Microcap Ledger Codexis, Inc. $CDXS
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Industrial Organic Chemicals
- Headquarters
- Redwood City, CA
- Fiscal year end
- December 31
- Shares outstanding
- 109,505,765 [10-Q 2026-08-11]
What the company doesAI summary of filing
Codexis develops and commercializes novel enzymes using its proprietary CodeEvolver directed evolution technology platform. The company generates revenue primarily through two business segments: its ECO Synthesis manufacturing platform, which provides enzymatic tools and processes for large-scale production of RNA interference (RNAi) therapeutics, and its small molecule pharma biocatalysis business, which supplies optimized enzymes to pharmaceutical manufacturers for use in drug manufacturing processes. The company is revenue-generating, with enzymes sold as biocatalysts for 18 approved commercial drugs and 15 drugs in clinical trials, while also offering contract development services and licensing its technology platform to major pharmaceutical companies. [10-K 2026-03-11]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $30.16M | −$20.71M | −$22.79M | $27.17M | [10-Q 2026-08-11] |
| FY ended Dec 2025 | $70.39M | −$43.97M | −$19.38M | $50.79M | [10-K 2026-03-11] |
| FY ended Dec 2024 | $59.34M | −$65.28M | −$49.41M | $19.26M | [10-K 2026-03-11] |
- Quarterly cash burn
- −$11.40M
- Cash runway Estimate
- ~7.2 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-10-28 | 81,377,855 | [10-Q 2024-10-31] |
| 2025-02-24 | 82,837,311 | [10-K 2025-02-27] |
| 2025-05-09 | 82,844,849 | [10-Q 2025-05-14] |
| 2025-08-08 | 90,267,464 | [10-Q 2025-08-13] |
| 2025-11-03 | 90,324,383 | [10-Q 2025-11-06] |
| 2026-03-05 | 90,869,349 | [10-K 2026-03-11] |
| 2026-05-01 | 90,896,567 | [10-Q 2026-05-07] |
| 2026-08-06 | 109,505,765 | [10-Q 2026-08-11] |
- Shelf registration
- S-3 filed 2024-05-02; declared effective 2024-05-14 [S-3 2024-05-02]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-13 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-11 | 10-Q | Quarterly report |
| 2026-08-11 | 8-K | Results of operations |
| 2026-07-29 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-07-27 | 8-K | Other events |
| 2026-07-24 | 424B5 | Prospectus or prospectus supplement |
| 2026-07-23 | 424B5 | Prospectus or prospectus supplement |
| 2026-07-23 | 8-K | Results of operations; Other events |
| 2026-07-20 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-06-22 | 8-K | Shareholder vote results |
| 2026-05-07 | 10-Q | Quarterly report |
| 2026-05-07 | 8-K | Results of operations |
Alerts for $CDXS
Email me when Codexis, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.